ReviewRenal failure2026
Anti-nephrin autoantibodies in post-transplant recurrence of focal segmental glomerulosclerosis: a review.
Review in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging studies have identified autoantibodies targeting the podocyte protein nephrin in patients with post-transplant recurrent focal segmental glomerulosclerosis (FSGS). These antibodies bind nephrin, directly disrupting its downstream signaling pathways. This disruption profoundly impacts podocyte structure and function, thereby enriching our understanding of antibody-mediated podocytopathies and their classification. The presence of these autoantibodies correlates with disease activity and offers considerable potential as an innovative biomarker for post-transplant recurrent FSGS. However, the precise contribution of these autoantibodies to the development of recurrent FSGS after transplantation remains elusive. In this review, we summarize the current research on anti-nephrin autoantibodies and discuss their applicability as a new biomarker for diagnosing, predicting outcomes, and guiding treatment in post-transplant recurrent FSGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.